The oncology landscape presents a strange paradox: the number of available investigator sites has surged by nearly 50% in five years, yet performance has remained flat. Up to 85% of trials still fail to meet their enrollment timelines. Why? The answer lies in a broken strategy. Too many sponsors rely on the “usual suspects”, large,…

What would saving 18 months and over $50 million on your lead asset’s development plan mean for your company? For most emerging biotechs, it’s the difference between market leadership and fighting for survival. This isn’t a hypothetical; it’s a real-world example of what’s possible with a truly integrated strategic and operational framework. The Scenario: An…

The finalization of the ICH E6(R3) Good Clinical Practice (GCP) guideline represents the most significant evolution in clinical trial management in a decade. For sponsors and CROs, this is not a minor update to be filed away; it is a mandatory shift to a new operating system. One that demands a move from a reactive…

The Harmonization Paradox In the world of global oncology trials, a dangerous illusion has taken hold: the harmonization paradox. With the full implementation of the EU’s Clinical Trial Information System (CTIS), it’s tempting to believe that operational harmony has been achieved. A single submission can launch a trial across multiple European countries, creating a powerful…

BIO International Convention in San Diego was, once again, a truly bright event. For four days, professionals from every corner of the life sciences ecosystem came together with a single uniting goal: to defeat diseases, improve lives, share enthusiasm, and find those who will be inspired by new ideas and visions. Our team at Accelsiors…

Swiss Biotech Day once again proved its standing as a central European hub for innovation, bringing together over 3,500 registrants from 58 countries, 150+ exhibitors, 31 international delegations, and more than 60 panel and roundtable discussions; a testament to the event’s remarkable scale and reach. For Accelsiors, attending Swiss Biotech Day was an opportunity to…

The EU AI Act is daunting. When you read the full text, it feels like you need a massive compliance department just to run a clinical trial.  But here is the secret: Not every tool is “High Risk.”  If you try to audit every chatbot, translation tool, and feasibility dashboard with the same scrutiny, you will paralyze your…

You didn’t commission a custom machine learning model. You didn’t sign a contract for “High-Risk AI.” So, you assume your upcoming EU study is safe from the new EU AI Act.  You are likely wrong.  In 2026, the biggest risk to clinical data integrity isn’t the software you build; it’s the “Invisible AI” embedded in the vendor platforms you already use.    Where AI…

Precision & Potency: The Future of Neuro-Immunology  Aligning the diagnostic safety of McDonald 2024 with the therapeutic power of CAR-T.  The High-Stakes Era of Neuro-Immunology For decades, Multiple Sclerosis (MS) drug development was a game of “maintenance”—using Disease Modifying Therapies (DMTs) to slow progression. But as we look toward 2026, the paradigm is shifting toward “immune reset.”  Therapies…

After exploring the complex legal, financial, and operational barriers stalling European clinical trials, the natural question is: What’s being done about it?  Fortunately, the response is not silence. The EU-X-CT initiative, a multi-stakeholder consortium of industry leaders, patient advocates, and academic experts, has developed a pragmatic and targeted 6-Point Action Plan. This is the official blueprint designed to dismantle the barriers…